NasdaqGS:TSHABiotechs
A Look At Taysha Gene Therapies (TSHA) Valuation After Key TSHA-102 Rett Syndrome Trial Milestones
Taysha Gene Therapies (TSHA) shares are in focus after the company dosed the first patient in its pivotal REVELA trial for TSHA-102 in Rett syndrome and confirmed FDA alignment on the ASPIRE safety trial.
See our latest analysis for Taysha Gene Therapies.
Even with the REVELA and ASPIRE trial progress, Taysha Gene Therapies’ recent share price returns have softened, with a 30 day share price return of a 15.81% decline and a year to date share price return of a 6.67% decline, while the 1 year...